Podcasts about castle biosciences

Dr. Fred Rosenberg interviews Jay Kreger, chief executive officer of CRH Medical, a GI solutions company that provides anesthesia services to gastroenterology practices at more than 150 ambulatory surgery centers in 18 states, about how independent practices can keep anesthesia care reliable and accessible for patients. Independent GI practices depend on anesthesia services for many of the procedures they perform, but face increasing difficulty maintaining anesthesia coverage, from competition with hospitals and health systems to reimbursement cuts from insurance companies. Partnering with a company that provides anesthesia and other services is one way practices can address these challenges and stay focused on patient care. Join Fred and Jay as they discuss what options exist for practices that want to partner with an anesthesia services company, and the steps independent practices can take to keep dependable anesthesia care in place for their communities. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, episode 92, presented by TissueCypher from Castle Biosciences

What exactly is Barrett's esophagus—and how do doctors determine who may be at higher risk? In Part 2 of this 4-part patient education series, leading gastroenterologist and advanced endoscopist Raman Muthusamy explains how Barrett's esophagus develops from chronic GERD and how it's diagnosed and evaluated in clinical practice in the United States. In this episode, you'll learn: ✔️ What Barrett's esophagus is ✔️ How chronic acid reflux can affect the esophagus ✔️ How Barrett's is diagnosed during endoscopy ✔️ How doctors assess risk for progression to cancer ✔️ Why early detection matters ✔️ How GI specialists guide treatment and follow-up care If you or someone you love experiences long-standing heartburn, reflux, or GERD symptoms, this episode provides trusted, expert-backed information to help you better understand Barrett's esophagus and what comes next. This episode is part of a 4-part patient education series sponsored by Castle Biosciences and produced in collaboration with leading U.S. clinicians dedicated to improving outcomes for patients with Barrett's esophagus.  

Dr. Michael Weinstein interviews Dr. Donevan Westerveld of Borland Groover in Jacksonville, Florida, about how his practice uses InterStim therapy to care for patients with fecal incontinence, a condition that affects an estimated 18 million Americans. Despite the availability of effective treatments, fecal incontinence is under-diagnosed and under-treated, and roughly two thirds of those affected never discuss it with a physician. InterStim is a small, implanted device developed by Medtronic that helps restore communication between the brain and the nerves that control bowel function. Join Dr. Weinstein and Dr. Westerveld as they discuss why Borland Groover brought InterStim therapy in-house, what it takes to integrate it into a GI practice, and how independent gastroenterologists can position themselves to care for patients who may otherwise go undiagnosed or untreated. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, episode 91, presented by TissueCypher from Castle Biosciences

As we wrap up Esophageal Cancer Awareness month, Dr. Parikh is joined by Dr. Caitlin Houghton, a foregut surgeon. They explore the significance of Barrett's esophagus as a precursor to esophageal cancer and the collaborative approach between gastroenterologists and foregut surgeons in managing the condition. This episode was brought to you by Castle Biosciences, maker of Tissue Cypher, a test designed to predict the risk of esophageal cancer in patients with Barrett's esophagus.

Kevin Harlen interviews Tom Wierzbowski, founder of Willow Risk Advisors, about how his firm helps physician practices and health care organizations manage professional liability and navigate today's malpractice insurance market. Willow Risk Advisors specializes in building specialty-specific insurance programs for physician groups and associations, working directly with carriers to structure coverage that reflects the distinct risk profiles of independent practices. Join Kevin and Tom as they explore how data collection and technology are improving underwriting and pricing for physician organizations, and what role carrier partnerships play in delivering risk management education and resources to providers and their practices. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, episode 90, presented by TissueCypher from Castle Biosciences

Dr. Lisa Mathew interviews Dr. Lyndsey Burton, a diagnostic radiologist and chief medical officer at Heidi, about how its AI-powered tools are helping clinicians reduce administrative burden and reclaim time for patient care. Heidi's suite of AI tools generates clinical notes in real time, provides access to evidence-based clinical research at the point of care, and manages patient scheduling and follow-up. Heidi can also help physicians identify what additional documentation is needed in a patient's record to support prior authorization requests. Dr. Burton provides a practical perspective on how independent GI practices can begin incorporating these tools into their workflow. Join Dr. Mathew and Dr. Burton as they explore how AI is reshaping clinical practice over the next decade, what practices should look for when choosing a technology partner, and what physicians need to understand about the real-world impact of these tools on patient care. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden MargolisGastro Broadcast, episode 89, presented by TissueCypher from Castle Biosciences

Barrett's esophagus can develop silently in people with chronic acid reflux (GERD)—and many don't realize their risk until after diagnosis. In this episode of Gastro Girl, Robin shares her powerful, real-life journey from ongoing reflux symptoms to a diagnosis of Barrett's esophagus—and how that moment changed everything. Like many patients, Robin faced confusion, fear, and unanswered questions about what her diagnosis meant and what to do next. After learning more about Barrett's esophagus, including risk factors, monitoring, and emerging tools like TissueCypher, she felt empowered to take a more active role in her care and have informed conversations with her healthcare team. In this episode, you'll learn: What Barrett's esophagus is and how it relates to GERD Common symptoms and warning signs patients often overlook What a diagnosis means for cancer risk and monitoring How patient education can transform fear into action Why self-advocacy matters in digestive health care Robin's story is a reminder that knowledge can change your path—and your outcomes. If you experience chronic heartburn or reflux, this episode offers important insights to help guide your next conversation with your doctor. This educational series is supported by Castle Biosciences. Robin's story reflects her personal experience. Gastro Girl provides evidence-based information to support informed patient-provider conversations and does not offer medical advice.  

With April being Esophageal Cancer Awareness month, today's episode delves into the misconceptions and harmful effects of heartburn, the myths surrounding reflux surgery, and the future of heartburn therapy. Dr. Dan Lister, past-president of the American Foregut Society, provides insights on the risks associated with heartburn and the potential of precision medicine in addressing esophageal adenocarcinoma.This episode was brought to you by Castle Biosciences, maker of TissueCypher, a test designed to predict the risk of esophageal cancer in patients with Barrett's esophagus.

Chronic heartburn and GERD are often brushed off as everyday issues—but for some patients, long-term reflux can quietly progress to Barrett's esophagus, the only known precursor to esophageal cancer. In Part 1 of this 4-part U.S.-focused patient education series, foregut surgeon Dr. Dan Lister, Founder of the Arkansas Heartburn Treatment Center, explains how reflux disease can evolve over time and why early recognition matters. In this episode, you'll learn: How chronic GERD can progress silently Why Barrett's esophagus matters—even when symptoms improve or disappear Key warning signs patients should never ignore How Barrett's is detected and risk is assessed in the U.S. Treatment approaches that may help reduce cancer risk Whether you've lived with reflux for years or are newly diagnosed, this episode provides clear, evidence-based guidance to help you take reflux seriously—and take action. This episode is part of a 4-part patient education series sponsored by Castle Biosciences and produced in collaboration with leading U.S. clinicians dedicated to improving outcomes for patients with Barrett's esophagus.  

Dr. Lisa Mathew interviews Dr. Steven Klein of Wilmington Gastroenterology about how UnitedHealthcare's recent 15% reimbursement reduction for anesthesia services provided by certified registered nurse anesthetists (CRNAs) could affect the way independent gastroenterology practices structure anesthesia services and maintain patient access to procedures such as colonoscopy. Dr. Klein explains how independent GI practices rely on CRNAs to provide anesthesia and how those services are structured within his practice, offering a practical view of how insurer policy decisions can reshape care delivery in outpatient endoscopy settings. Join Dr. Mathew and Dr. Klein as they examine how this policy compounds existing pressures such as prior authorization requirements and site-of-service restrictions, the downstream effects on colorectal cancer screening and other procedures, and what insurers and policymakers need to understand about the real-world impact of these decisions on patient access. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, episode 88, presented by TissueCypher from Castle Biosciences

Dr. Lisa Mathew interviews Dru Riddle, Professor of Professional Practice and Director of Clinical Education in the School of Nurse Anesthesia at Texas Christian University and a past president of the American Association of Nurse Anesthesiology, about the role certified registered nurse anesthetists (CRNAs) play in providing anesthesia for GI care. CRNAs are essential to maintaining access to GI procedures that require anesthesia, particularly in outpatient endoscopy centers where many GI practices rely on CRNAs as their primary anesthesia workforce. UnitedHealthcare recently implemented a 15 percent reduction in reimbursement for anesthesia services provided by CRNAs, which could make it harder for outpatient endoscopy centers to maintain anesthesia coverage, push more care into hospital settings, and limit timely access to GI procedures. Join Dr. Mathew and Dr. Riddle as they discuss the importance of CRNA-delivered anesthesia, the potential impact of insurer policy changes on patient access to GI care, and practical considerations for independent GI practices that are navigating these issues. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 87, presented by TissueCypher from Castle Biosciences

Dr. Fred Rosenberg interviews Chi Kapoor, founder and managing partner of KITC, a cybersecurity firm that works with healthcare organizations to protect sensitive data, maintain regulatory compliance, and strengthen resilience against digital threats. As cyberattacks against healthcare organizations continue to rise, private practice gastroenterology groups face growing exposure due to interconnected systems, third-party vendors, legacy medical devices, and increasing reliance on digital tools. Kapoor discusses why medical practices are frequent targets for ransomware and phishing attacks, where GI practices are most vulnerable, and how risks can originate outside a practice's direct control through vendors, cloud platforms, and outdated infrastructure. Join Rosenberg and Kapoor as they explore practical, cost-conscious steps GI practices can take to strengthen cybersecurity, build a culture of security among staff, address vulnerabilities without disrupting patient care, and prepare for emerging risks tied to telehealth, AI-enabled tools, and cloud-based systems. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 86, presented by TissueCypher from Castle Biosciences

Dr. Lisa Mathew interviews Dr. Caitlin Houghton, a foregut surgeon at the Keck School of Medicine of USC and MemorialCare Orange Coast Medical Center. Dr. Houghton specializes in the management of GERD and Barrett's Esophagus, focusing on identifying patients at highest risk for esophageal cancer and using advanced endoscopic techniques to personalize care. GERD Awareness Week coincides with the start of the holiday season, a time when patients often notice their reflux symptoms worsening. Dr. Houghton discusses emerging trends in GERD and Barrett's Esophagus that private practice gastroenterologists should be tracking. She also shares insights from cases like her uncle Pat, who developed long-segment Barrett's with minimal reflux symptoms, and offers guidance on how clinicians can better counsel patients who may be asymptomatic but still at risk. Join Dr. Mathew and Dr. Houghton as they explore practical approaches to risk stratification, indications for upper endoscopy, and how to weigh treatment options for patients with Barrett's esophagus. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 85, presented by TissueCypher from Castle Biosciences

Dr. Lisa Mathew interviews Mallika Khandelwal, founder and CEO of Squad Health, and Tasha Cieslak, practice manager of Louisiana Gastroenterology Associates about how independent GI practices can streamline the management of complex prescription workflows. Squad Health is an AI-enabled healthcare technology company developing solutions to streamline access to specialty medications and reduce the workload around prior authorizations and appeals. Join Lisa, Mallika, and Tasha as they discuss how technology can ease administrative burden in gastroenterology, what early automation looks like inside a busy practice, and the innovations ahead for practices adopting AI-driven solutions to improve efficiency and access to care. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 84, presented by TissueCypher from Castle Biosciences

Dr. Lisa Mathew interviews Dr. Sahil Patel and Patrick Leonard of SideBy Care, a virtual platform that partners with GI practices to support patients with disorders of gut-brain interaction such as irritable bowel syndrome and functional dyspepsia. SideBy Care provides gut-brain therapy, nutrition counseling, and behavioral support through a multidisciplinary team - services that are typically covered by insurance and integrate seamlessly into existing GI practice workflows. Join Dr. Mathew, Dr. Patel, and Patrick Leonard as they explore how collaboration between gastroenterologists and digital care teams can expand access, improve outcomes, and enhance the patient experience. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 83, presented by TissueCypher from Castle Biosciences

Dr. Michael Weinstein interviews Dr. Casey Chapman, chief medical officer of the GI Alliance, and Jonathan Ng, founder and CEO of Iterative Health, about a new strategic partnership to expand access to clinical trials across 400 GI Alliance locations in 20 states. By integrating the GI Alliance's established research sites with Iterative Health's Site Network, the collaboration creates one of the largest GI-focused research networks in the country. Dr. Chapman and Mr. Ng highlight how private practice gastroenterology can play a leading role in advancing research by making clinical trials more accessible to patients in community settings. Join Dr. Weinstein, Dr. Chapman, and Mr. Ng as they explore the growth of clinical research in private practice and how collaboration can advance the field of gastroenterology. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 82, presented by TissueCypher from Castle Biosciences

Dr. Naresh Gunaratnam interviews Dr. Larry Kim of South Denver GI, where he has spent his career advancing patient care, expanding advanced endoscopy and research programs, and fostering a practice that champions diversity and collaboration in independent GI. As the 120th president of the American Gastroenterological Association (AGA), Dr. Kim builds on 25 years of leadership advancing research, education, advocacy, and quality initiatives that strengthen the specialty and support gastroenterologists nationwide. He is committed to fostering an inclusive, patient-centered specialty and championing the next generation of GI leaders. Join Dr. Gunaratnam and Dr. Kim for a conversation about his vision for AGA, the challenges and opportunities ahead for gastroenterology, and how community practice and national leadership intersect to advance patient care. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 81, presented by TissueCypher from Castle Biosciences

Dr. Fred Rosenberg interviews Dr. Reezwana Chowdhury, a gastroenterologist at Johns Hopkins specializing in inflammatory bowel disease (IBD), and Tina Aswani-Omprakash, executive director of the South Asian IBD Alliance. The South Asian IBD Alliance creates resources, research, and education for IBD patients of South Asian origin and healthcare providers - to minimize disparities, dispel stigma, promote early diagnosis, and improve access to treatment. Join Dr. Rosenberg, Dr. Chowdhury, and Ms. Aswani‑Omprakash as they explore how physicians independent GI practices can use these tools to provide culturally competent, personalized care, improving outcomes for South Asians living with IBD. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 80, presented by TissueCypher from Castle Biosciences

Following the June 23 OX40 webinar, Dr. Eichenfield, Dr. Simpson, and Dr. Wan continue the conversation with a look ahead at the future of OX40 therapies and their potential to change the course of disease. They also unpack the complex concept of remission in atopic dermatitis—what it means, how it's defined, and whether it's truly achievable.To watch the OX40 webinar, please click here.Disclosures:Lawrence Eichenfield, MD has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, CorEvitas, Dermavant, Eli Lilly, Forte, Galderma, Incyte Corporation, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Target RWE, T-Rex, and UCB.Eric Simpson, MD reports personal fees from AbbVie, Aclaris Therapeutics, Amgen, Arcutis, Astria Therapeutics, Attovia Therapeutics, Inc., Bambusa Therapeutics Inc., Castle, CorEvitas, Dermira, Eli Lilly, Evomunne, FIDE, Impetus Healthcare, Incyte, Innovaderm Reche/ Indero, Inmagene Biopharmaceuticals, Janssen, LectureLinx (LLX), Leo, NUMAB Therapeutics AG, Pfizer, Recludix Pharma, Regeneron, Roche Products Ltd, Sanofi-Genzyme, SITRYX TherapeuticsEric Simpson, MD reports grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, Dermavant, CorEvitas, Dermira, Eli Lilly, Incyte, Pfizer, Regeneron, Sanofi-Genzyme, Target, VeriSkinJoy Wan, MD Sun Pharmaceuticals - consulting (DMC), Astria Therapeutics - consulting (ad board), Galderma - fellowship funding (paid to Johns Hopkins)

My heartburn patients frequently ask me: how much chocolate can I have? What about wine? Coffee? Dillon Martin is a registered dietician who specializes in diabetes, weight optimization and gastroesophageal disorders. He answers these questions and gives practical dietary advice for those suffering with GERD. Today's episode is brought to you by Castle Biosciences, maker of TissueCypher, a test designed to predict the risk of esophageal cancer in patients with Barrett's esophagus.

This engaging and informative webinar explores the role of OX40 and OX40L in pediatric dermatology. OX40: Innovative Insights and Therapeutic Potential in Pediatric Dermatology brings together experts in the field to discuss emerging research, mechanisms of action, and the implications of targeting the OX40 pathway for treating chronic inflammatory skin diseases in children. To view the video version of this webinar, please click here. Disclosures:Lawrence Eichenfield, MD has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, CorEvitas, Dermavant, Eli Lilly, Forte, Galderma, Incyte Corporation, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Target RWE, T-Rex, and UCB.Eric Simpson, MD reports personal fees from AbbVie, Aclaris Therapeutics, Amgen, Arcutis, Astria Therapeutics, Attovia Therapeutics, Inc., Bambusa Therapeutics Inc., Castle, CorEvitas, Dermira, Eli Lilly, Evomunne, FIDE, Impetus Healthcare, Incyte, Innovaderm Reche/ Indero, Inmagene Biopharmaceuticals, Janssen, LectureLinx (LLX), Leo, NUMAB Therapeutics AG, Pfizer, Recludix Pharma, Regeneron, Roche Products Ltd, Sanofi-Genzyme, SITRYX TherapeuticsEric Simpson, MD reports grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, Dermavant, CorEvitas, Dermira, Eli Lilly, Incyte, Pfizer, Regeneron, Sanofi-Genzyme, Target, VeriSkinJoy Wan, MD Sun Pharmaceuticals - consulting (DMC), Astria Therapeutics - consulting (ad board), Galderma - fellowship funding (paid to Johns Hopkins)

In the final episode of our 4-part series on GERD and Barrett's Esophagus, we move beyond awareness to focus on action. What should patients actually do after diagnosis—and how can they take charge of their care journey? We're joined by Tedra Gray, a seasoned Advanced Practice Provider, who shares real-world examples and practical advice for patients navigating chronic reflux, Barrett's Esophagus, or treatment follow-up. You'll learn: Why early diagnosis and follow-up matter What can happen if Barrett's Esophagus is left untreated How shared decision-making helps build the right care plan The different approaches for patients at low, moderate, or high risk Whether you're newly diagnosed or managing long-term reflux, this episode offers compassionate, expert-backed guidance to help you feel informed and empowered. Missed the earlier episodes? Catch up here: Part 1 – From Reflux to Risk: How Heartburn and GERD Could Lead to Esophageal Cancer https://gastrogirl.com/podcast/from-reflux-to-risk-how-heartburn-and-gerd-could-lead-to-esophageal-cancer/ Part 2 – Barrett's Esophagus: The Hidden Risk of Chronic Heartburn https://gastrogirl.com/podcast/barretts-esophagus-the-hidden-risk-of-chronic-heartburn/ Part 3 – Managing Barrett's Esophagus: Treatments and Risk Reduction https://gastrogirl.com/podcast/managing-barretts-esophagus-treatments-risk-reduction/  This series is sponsored by Castle Biosciences and produced in collaboration with leading clinicians and researchers committed to improving patient outcomes.    

In Part 3 of our 4-part series on GERD and Barrett's Esophagus, we're joined by Dr. Caitlin Houghton, a foregut surgeon with Keck Medicine of USC, to discuss what happens after Barrett's Esophagus is diagnosed—and how patients can reduce their cancer risk and manage the condition effectively. From reflux control to endoscopic eradication therapy (EET), and in some cases, surgery, Dr. Houghton breaks down the latest treatment strategies and what patients need to know. This episode offers practical advice, expert insights, and real hope for those navigating life with Barrett's. Topics include: What Barrett's Esophagus is and why it matters How doctors decide when and how to treat The role of EET, medications, and lifestyle changes When surgery may be necessary Tips for patients to advocate for their care Missed the earlier episodes? Catch up here: Part 1 – From Reflux to Risk: How Heartburn and GERD Could Lead to Esophageal Cancer https://gastrogirl.com/podcast/from-reflux-to-risk-how-heartburn-and-gerd-could-lead-to-esophageal-cancer/ Part 2 – Barrett's Esophagus: The Hidden Risk of Chronic Heartburn https://gastrogirl.com/podcast/barretts-esophagus-the-hidden-risk-of-chronic-heartburn/ This series is sponsored by Castle Biosciences and produced in collaboration with leading clinicians and researchers committed to improving patient outcomes.  

Dr. Fred Rosenberg interviews Jess Ivy, the Head of Nutrition at Sylvan Health, which focuses on empowering patients with chronic diseases through affordable and accessible nutrition counseling. Sylvan health provides a comprehensive nutrition service line to support the broader care model within GI practices and to help addresses dietary and lifestyle factors that can play a positive role in digestive health. Join Dr. Rosenberg and Jess as they explore how independent GI practices can integrate evidence-based nutrition programs into their care plans and potentially improve patient outcomes and reduce costs. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 79, presented by TissueCypher from Castle Biosciences

In part 2 of our 4-part series on GERD and Barrett's Esophagus, we take a closer look at what Barrett's esophagus is, how it develops from chronic acid reflux, and why early detection is essential to reducing the risk of esophageal cancer. We're joined by Dr. Raman Muthusamy, a nationally recognized expert in gastroenterology and advanced endoscopy, who explains how Barrett's is diagnosed, the latest tools and technologies involved, and how a team-based approach improves outcomes. If you or someone you care about struggles with long-term heartburn or GERD, this episode offers critical insights to help you take action before it becomes something more serious. Missed Part 1? Listen or watch  now:From Reflux to Risk: How Heartburn and GERD Could Lead to Esophageal Cancer https://bit.ly/3Fvzf4o This series is sponsored by Castle Biosciences and produced in collaboration with leading clinicians and researchers dedicated to improving patient care and outcomes.

Dr. Naresh Gunaratnam interviews Dr. Deepti Mehtani, vice president of clinical solutions for NextGen Healthcare, about its recently launched Gastro Suite, which brings gastro-specific workflows to the NextGen electronic health record to streamline repetitive tasks, deliver faster insights, and support an enhanced patient experience. The suite is easily integrated with other solutions from NextGen Healthcare, enabling hands-free mobile documentation with NextGen Ambient Assist, enhanced patient engagement with the NextGen Closed Loop Patient and Practice Experience, billing automation, cloud hosting, and advanced interoperability. Join Dr. Gunaratnam and Dr. Mehtani as they explore what independent GI practices should be considering when looking for an industry partner to help improve their data and technology platforms. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 78, presented by TissueCypher from Castle Biosciences

Is your heartburn more dangerous than you think? In this first episode of our 4-part patient-focused series, we break down the serious risks of untreated acid reflux and gastroesophageal reflux disease (GERD)—including its connection to Barrett's esophagus, the only known precursor to esophageal cancer. Dr. Dan Lister, a leading Foregut Surgeon and founder of the Arkansas Heartburn Treatment Center, joins us to explain: How GERD can progress silently over time Why Barrett's esophagus matters—and how it's detected What red flags to look out for (including when reflux suddenly disappears) The latest treatment options that could help prevent cancer Whether you've been living with reflux for years or are newly diagnosed, this episode is packed with life-saving insights. This special 4-part series is sponsored by Castle Biosciences and produced in collaboration with leading clinicians and researchers dedicated to improving patient outcomes.  

Dr. Lisa Mathew interviews Dr. Brittany Panico, a rheumatologist in Colorado Springs who recently wrote an op-ed calling for reforms to the 340B program to require more transparency and reporting on how 340B discounts are passed on to patients. The 340B Program is a federal drug pricing program that allows certain hospitals and clinics to buy medications at steep discounts to support medication access for underserved patients, with the expectation that these savings would be passed on to patients. But critics argue that the program's growth has led to unintended consequences, such as market consolidation. And some studies suggest that 340B discounts may not translate into increased care or lower costs for vulnerable populations. Join Dr. Mathew and Dr. Panico as they discuss Dr. Panico's experience as an employed physician in a 340B hospital system and as an independent physician, and how the lack of oversight in the program may be making it harder for specialists to deliver the best patient care. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 77, presented by TissueCypher from Castle Biosciences

Dr. Lisa Mathew interviews Vetri Venthan Elango and Dr. Renu Dhanasekaran MD PhD, the founders of Arithmedics, a company that uses generative AI and data intelligence to reduce administrative time and costs for providers. Arithmedics uses generative AI and data intelligence to reduce billing mistakes and claim denials. Its software generates and explains codes to streamline the billing process and uses data from completed claims to reduce future denials. Join Dr. Mathew, Dr. Elango and Dr. Dhanasekaran as they discuss what physicians need to understand about implementing AI platforms for administrative tasks such as billing and coding. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 76, presented by TissueCypher from Castle Biosciences

Episode 31, In this episode, we look at redefining Gastroenterology: Mentorship, Innovation, and the Future of Interventional Endoscopy with Dr. Srinadh Komanduri Episode Summary: In this episode of The Interventional Endoscopist, host Dr. Mankanwal Sachdev reconnects with his longtime mentor, Dr. Srinadh Komanduri of Northwestern University. The two dive into Dr. Komanduri's unique training path, his role in building Northwestern's interventional endoscopy program, and how the field of GI is shifting away from traditional definitions toward a more therapeutic and innovation-driven future. The conversation covers the launch of Northwestern's system-wide GI integration, the impact of tools like TissueCypher for risk stratification in Barrett's esophagus, and the critical need to rethink GI fellowship structure. They also touch on barriers to technology adoption, the role of AI in operational efficiency, and how innovation can (and must) scale beyond a few experts to change care across systems. Topics Covered: Dr. Komanduri's mentorship and hybrid fellowship experience Building an interventional GI network across 11 hospitals Moving beyond the “general GI” label Risk stratification and innovations in Barrett's esophagus care AI's role in reducing burnout and boosting clinical efficiency Future models for GI training and specialization Barriers to adoption and how to drive systemic innovation Sponsored by: Castle Biosciences – maker of TissueCypher®, a test to predict esophageal cancer risk in Barrett's esophagus

Dr. Lisa Mathew interviews Gary Trendel, vice president of Endoscopy Solutions Ecosystem and Dr. Ruhy Patel, Medical and Scientific Affairs lead for the Endoscopy Solutions Ecosystem and Digital Units at Olympus. Odin Medical, an Olympus company, recently received 510K clearance from the U.S. Food and Drug Administration for the first cloud-based Artificial Intelligence technology designed to assist gastroenterologists in detecting colorectal polyps during colonoscopy procedures. The CADDIE, or computer-aided detection (CADe) device, works by analyzing colonoscopy video in real-time and using visual markers to alert the endoscopist to the potential presence of polyps. A prospective, multi-center randomized controlled trial successfully demonstrated the efficacy and safety of the CADDIE device, underscoring its potential to enhance detection capabilities and patient care without increasing procedural risks or duration. Join Dr. Mathew, Mr. Trendel, and Dr. Patel as they discuss the potential for AI in improving patient care, and what independent GI physicians should understand about AI platforms that assist in detecting polyps during colonoscopy. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 75, presented by TissueCypher from Castle Biosciences

April is Esophageal Cancer awareness month. Dr. Parikh interviews fellow gastroenterologist, Dr. George Sun. They discuss the epidemiology, risk factors, and symptoms of esophageal cancer before briefly providing an overview of treatment modalities. This episode is brought to you by Castle Biosciences, maker of TissueCypher, a test designed to predict the risk of esophageal cancer in patients with Barrett's esophagus.

Dr. Lisa Mathew interviews Jeff Glueck, co-founder and CEO of Salvo Health, a technology company that partners with GI practices to support patients with chronic GI conditions through a virtual clinic experience using a multi-disciplinary care team. Salvo Health's framework seeks to restore balance and improve chronic symptoms by considering the interconnected roles that the mind, body and gut play in a person's health. Join Lisa and Jeff as they discuss what GI physicians should consider in partnering with technology platforms that provide cross-functional care to their patients. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 74, presented by TissueCypher from Castle Biosciences

Dr. Lisa Mathew interviews Dr. Vijay Yajnik, vice president and head of U.S. Medical, Gastroenterology, at Takeda about how the prevalence of eosinophilic esophagitis (EoE) is increasing, and evidence is growing that EoE is not a rare disease, but an underdiagnosed one. Approximately one in 2000 people in the U.S. live with EoE, and the incidence and prevalence of eosinophilic esophagitis have steadily increased over time. Join Dr. Mathew and Dr. Yajnik as they explore progress that has been made in diagnosing and treating EoE, and some recent studies that could influence patient care. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 73, presented by TissueCypher from Castle Biosciences

I am excited to share insights from the Interventional Endoscopist podcast featuring Dr. Sachin Wani! The discussion centered on Barrett's esophagus, and strategies to improve detection and risk stratification Key takeaways: • The rising incidence of esophageal adenocarcinoma makes early detection crucial. Yet, survival rates remain low, highlighting the need for improved strategies • PEEC and PEEN underscore the issue of missed lesions during endoscopy, emphasizing the need for high-quality exam. • PEEC (postendoscopy esophageal adenocarcinoma) refers to cancer detected before the next recommended surveillance endoscopy in patients with non-dysplastic Barrett's esophagus.  • PEEN (postendoscopy esophageal neoplasia) is a composite endpoint of high-grade dysplasia or cancer detected before the next recommended surveillance exam • A high-quality endoscopic exam is paramount, including meticulous inspection, standardized classification, and advanced imaging techniques like chromoendoscopy.  • A 10-step approach to a high-quality exam includes identifying landmarks, spending adequate time inspecting the Barrett's segment, cleaning the distal esophagus, and using high-definition white light endoscopy and virtual chromoendoscopy • While the Seattle biopsy protocol is standard, it has limitations due to sampling errors • WATS (Wide Area Transepithelial Sampling) can enhance neoplasia detection as an adjunct to the Seattle protocol by sampling the entire Barrett's segment. • AI (artificial intelligence) holds promise for lesion detection, improved diagnostic accuracy, and quality assessment of endoscopic exams. AI platforms may help identify visible lesions and predict histology, as well as assess the quality of the endoscopic examination. • The Tissue Cypher test can aid in risk stratification by analyzing biomarkers to predict the risk of progression to high-grade dysplasia. It can also predict prevalent high-grade dysplasia or cancer.  • Dr. Wani also shared his journey into medicine, influenced by his family, and the challenges faced by foreign medical graduates. A key message was the importance of continuous improvement in endoscopic techniques and the integration of new technologies to combat esophageal adenocarcinoma   This episode was sponsored by Castle Biosciences the makers of the TIssue Cypher Test.

Dr. Michael Weinstein interviews Dr. Ali Rezaie, a GI physician-scientist who specializes in microbiome research and gastrointestinal motility disorders. His recent study, which won an award at ACG, showed that a new elemental diet from mBIOTA Labs can significantly improve patient compliance. The study assessed mBIOTA Elemental, a palatable elemental diet designed to address the barriers of poor taste and low adherence associated with traditional elemental diets. Participants using mBIOTA Elemental had complete compliance throughout the two-week therapy, a critical outcome when managing gastrointestinal disorders such as Small Intestinal Bacterial Overgrowth (SIBO), Inflammatory Bowel Disease (IBD), and other complex GI conditions. Join Dr. Weinstein and Dr. Rezai as they explore how new innovations in elemental diets can help support patients with specific GI conditions and needs. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 72, presented by TissueCypher from Castle Biosciences

Dr. Michael Weinstein interviews Dr. Larry Kosinski about new data from SonarMD describing the association between anxiety and increased risk for flares and higher disease severity in inflammatory bowel disease (IBD), and emphasizing the importance of integrating mental health support within value-based care models for IBD management. According to the study, Patients with anxiety symptoms were significantly more likely to have high disease severity, and over a six-month follow-up, patients with anxiety exhibited a nearly doubled flare rate. The study suggests that mental health factors like anxiety play a critical role in the clinical course of IBD and that by identifying and addressing psychological contributors, value-based care models can be refined to better support patients with chronic digestive diseases. Join Dr. Weinstein and Dr. Kosinski as they explore the importance of a multidisciplinary approach to IBD management and what GI physicians can do to ensure that their patients have the resources they need. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 71, presented by TissueCypher from Castle Biosciences

In episode 29 of the Interventional Endoscopist Podcast, join us for an insightful conversation with Dr. Legett from the Mayo Clinic, Rochester. We delve into his extensive experience in treating esophageal disorders, focusing on Barrett's esophagus. Dr. Legett shares his journey and training at Mayo Clinic, highlighting his expertise in leveraging artificial intelligence and precision medicine, such as the TissueCypher test, to enhance early detection and management of Barrett's esophagus and esophageal cancer. The episode explores the challenges of diagnosing dysplasia, the transformative potential of AI in standardizing pathology, and improving patient care. Additionally, we discuss the role of molecular profiling in risk stratification and emphasize the critical need for ongoing research to optimize management strategies for Barrett's esophagus. This episode is proudly sponsored by Castle Biosciences, the innovators behind TissueCypher, a test designed to predict esophageal cancer risk in patients with Barrett's esophagus.

In this Gut Doctor episode, Dr. Parikh takes on the patient role as PA Sarah Enslin discusses diagnosis and management of Barrett's esophagus. Sarah Enslin is a physician assistant at the University of Rochester Medical Center and Vice Chair of American College of Gastroenterology's Advanced Practice Provider committee. Today's episode is brought to you by Castle Biosciences, maker of TissueCypher, a test designed to predict the risk of esophageal cancer in patients with Barrett's esophagus.

Host Dr. Lisa Mathew interviews Kathleen Teixeira, vice president of public policy and advocacy for the American Gastroenterological Association. Lisa and Kathleen discuss what policies will be in play in 2025 and how GI physicians can get involved to advocate for their patients and their practices. Join Lisa and Kathleen as they explore how physicians can get involved in shaping the policies that will affect patient care and practice management with the new Congress and Administration. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 69, presented by TissueCypher from Castle Biosciences

Kevin Harlen interviews Laura Wingate, chief education, support, and advocacy officer with the Crohn's & Colitis Foundation about a recent survey which shows that more than 40 percent of patients with inflammatory bowel disease (IBD) have made significant financial trade-offs to afford their healthcare. The survey, published in Inflammatory Bowel Diseases, included responses from more than 2,200 IBD patients and caregivers, who highlighted persistent challenges. Among respondents, 30 percent reported giving up vacations or major household purchases, 22 percent increased their credit card debt, and 21 percent cut back on essential items such as food, clothing, or basic household items. Join Kevin and Laura as they explore what can done to ensure that IBD patients can access the medications they need without undue financial hardship. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 69, presented by TissueCypher from Castle Biosciences

Dr. Fred Rosenberg interviews Dr. Ruchi Mathur, director of the Diabetes Program in the Division of Endocrinology, Diabetes and Metabolism and an endocrinologist at the Weight Loss Center, at Cedars-Sinai. Cedars-Sinai recently released a study which found that patients who take a class of widely prescribed medications (GLP-1) to manage diabetes and obesity may require extra preparations before undergoing endoscopic procedures. Join Dr. Rosenberg and Dr. Mathur as they explore how gastroenterologists can advise patients who take GLP-1 medications when preparing for endoscopic procedures, to have the best results. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 68, presented by TissueCypher from Castle Biosciences

In today's episode of the Innovation series, Dr. Parikh sits down with Mindy Mintz Mordecai, president and CEO of the Esophageal Cancer Action Network (ECAN). They discuss Mindy's journey, the origins of ECAN, and how it continues to support current and future patients with esophageal cancer. Today's episode was brought to you by Castle Biosciences, maker of TissueCypher, a test designed to predict the risk of esophageal cancer in patients with Barrett's esophagus. 

Get an exclusive look at the cutting-edge research on ocular melanoma, uveal melanoma, retinoblastoma, and more in this eye-opening video on eye cancer in 2024!Eye on Research 2024: Advancing Innovation in Cancer Research and TreatmentDescription:Welcome to the second annual "Eye on Research 2024" event! We are thrilled to be joined by a panel of esteemed doctors and researchers who are leading groundbreaking efforts in cancer research and treatment. Special thanks to all our guest doctors, including Dr. Correa and others, for their dedication to improving patient outcomes through innovation and cutting-edge science.Dr. Correa: Leading discussions on the latest advancements in cancer immunotherapy and the importance of personalized medicine in treating cancer patients.Additionally, we extend our gratitude to our generous sponsors, including Castle Biosciences, IDEAYA Biosciences, Aura Biosciences, TriSalus Life Sciences, Immunocore, Delcath, and Replimune, for making this event possible.Join us for this exciting session as we explore new frontiers in cancer research, including clinical trials, treatment strategies, and the potential for future breakthroughs. Thank you to everyone for being part of this incredible journey!

une in now to dive into Presley Jackson's incredible Polaroid project! Diagnosed at just 13, Presley has been unstoppable in sharing his journey these last few years, with the unwavering support of his amazing mom, Stephanie. His outlook in the face of #ocularmelanoma, his plaque treatment with Dr. Shields, and his transition into adulthood is nothing short of inspiring. Don't miss this video, and get ready for an exciting YouTube and Podcast channel launch later this week! A massive thank you to everyone who supports, organizes fundraisers, and participates in the Lookin' For A Cure For Ocular Melanoma 5k races! We can't achieve our goals without you, and we value every contribution! Please think about making a donation today to help ACIS continue to fund patient care, research, and educational programs like The Eye Believe Podcast. #ChildhoodCancerAwarenessMonth A special shoutout to Castle Biosciences, Inc. for sponsoring the podcast platforms!

Hope is on the Horizon with Dr. Shields! Please help us share this video to spread the hope in #ocularmelanoma Legendary Dr. Shields discloses the importance of early detection, advances in research, and helps you understand YOUR brand of #uvealmelanoma   Got questions? Share below and let us know so we can bring her back to bring you more of what you'd like to know!

Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique characteristics of prurigo nodularis (PN) and its clinical definition and explore how some of these characteristics are shared with atopic dermatitis, including underlying type 2 inflammation. They also discuss the need to raise awareness of this disease among both physicians and patients and educate that this is not a psychodermatological disorder. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr. Shawn Kwatra is an advisory board member/consultant for Abbvie, Amgen, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Dermavant, Galderma, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi. Dr. Sonja Ständer was speaker and/or consultant and/or Investigator and/or has received research funding from AbbVie, Almirall, Beiersdorf, BMS, Clexio, Eli Lilly, FomF, Galderma, German Research Foundation (DFG), Integrity CE, Kiniksa, Leo Pharma, L'Oréal, MEDahead, Moroscience, NACCME, Novartis, Omnicuris, P.G. Unna Academy, Pfizer, Sanofi, TouchIME, UCB, Vifor, and WebMD. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400085- 1.0 - 08/2024 MAT-US-2408113 v1.0-P Expiration Date: 08/13/2026

Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the challenges associated with diagnosis of atopic dermatitis of the hands and feet and how disease severity can be assessed in clinical practice. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer. Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2402602- 1.0 - 05/2024 MAT-US-2405594 v1.0 - P Exp Date: 06/04/2026

Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the epidemiology, clinical presentation, and classification of atopic dermatitis of the hand and feet as well the as quantifying the multidimensional burden it has on patients' quality of life in clinical practice. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer. Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400314 - 1.0 - 06/2024  MAT-US-2405589 v1.0 - P Exp Date: 06/04/2026

Towny Robinson is the CEO of JayMac Pharmaceuticals and the inventor of EnLyte and EnBrace HR. He is a national expert on Methylation Biochemistry/Genetics and Psychiatric Disorders. Visit his website to learn more: www.enlyterx.com/about-enlyte www.enlyterx.com/about-enlyte Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc.